72 lines
3.1 KiB
HTML
72 lines
3.1 KiB
HTML
{{define "nav"}}
|
|
<div>
|
|
<p class="sidebar-label">subjects</p>
|
|
<div class="skill-list">
|
|
<div class="skill-item">opinion</div>
|
|
<div class="skill-item">due diligence</div>
|
|
<div class="skill-item">performance</div>
|
|
</div>
|
|
</div>
|
|
|
|
{{end}}
|
|
|
|
{{define "body"}}
|
|
<section id="research">
|
|
<div class="page-header">
|
|
<h2 class="page-title">Equity Research</h2>
|
|
</div>
|
|
|
|
<div class="exp-card">
|
|
<div class="exp-header">
|
|
<span class="exp-title">Story vs Fundamental value</span>
|
|
</div>
|
|
<p class="exp-body">
|
|
|
|
The truth I keep coming back to is simple: find value grounded in the fundamental numbers of a company.
|
|
<br>
|
|
My approach is rooted in fundamental analysis using SEC filings (10-K, 10-Q), earnings reports, profitability, liquidity, risk factors, and long-term business sustainability. In low-transparency situations I rely on structured cross-validation across sources.
|
|
<br>
|
|
A pattern I keep seeing is CEOs speaking just close enough to reality to generate a short-term price boost, then moving the goalposts when reality catches up. What companies state in filings and what they communicate to retail or even professional investors can be two very different stories. Guidance only needs to reach far enough into the future to say almost anything.
|
|
</p>
|
|
</div>
|
|
<br>
|
|
<div class="section-head">
|
|
<h2>Current stock analysis</h2>
|
|
</div>
|
|
<div class="exp-card link" onclick="window.open('/static/pdf/mstr.pdf', '_blank')">
|
|
<div class="exp-header">
|
|
<span class="exp-title">MSTR: Strategy<span style="color: red;"> (Sell)</span></span>
|
|
<span class="exp-tag">due diligence</span>
|
|
</div>
|
|
<p class="exp-body">
|
|
The company only owns btc by issuing debt and preferred stock offering.
|
|
<br>
|
|
The company is a ponzi scheme at its best.
|
|
</p>
|
|
</div>
|
|
<br>
|
|
<div class="exp-card link" onclick="window.open('/static/pdf/novo.pdf', '_blank')">
|
|
<div class="exp-header">
|
|
<span class="exp-title">Novo.B/NVO: Novo Nordisk A/S<span style="color: green"> (buy)</span></span>
|
|
<span class="exp-tag">due diligence</span>
|
|
</div>
|
|
<p class="exp-body">
|
|
The product sales of wieght loss drugs are highclass, pipeline is undervalued.
|
|
<br>
|
|
Pipeline and wegovy pil is not reconsiced correctly as high focus on expireation of current sold product. high pisimistic view of pipeline.
|
|
</p>
|
|
</div>
|
|
<br>
|
|
|
|
<div class="section-head">
|
|
<h2>Equity portfolio performance</h2>
|
|
</div>
|
|
<div class="exp-card">
|
|
<div hx-get="/static/components/eq.html" hx-trigger="load" hx-swap="outerHTML">
|
|
<span class="spinner">Loading chart...</span>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
</section>
|
|
{{end}} |